Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
O. V. Dorozhko, G. I. Kovalev, R. M. Salimov · 2006 · RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006
What does this source report?
Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.
- Population and setting
- Patent reports 10 MS cases and a separate 10-person chronic-fatigue group; one MS case described
- Evidence type
- Patent / reported experiments
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
- The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
- Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Patent full text
Review depth: Clinical example and patent dates checked
Source access and review scope
Source text reviewed at the access level stated; no independent verification of patient data.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Cite and trace this record
Original source: O. V. Dorozhko, G. I. Kovalev, R. M. Salimov. Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006 2006.
Molekul research summary: https://molekul.io/research/bemitil-ms-2006-patent. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Bemitil
A benzimidazole-derived actoprotector, also indexed as bemethyl and Metaprot. Research spans patient asthenia, occupational settings, neuromuscular and liver studies, metabolism and preclinical safety; these are research contexts, not established uses.
Piracetam
Piracetam, marketed as Nootropil, connects the original nootropic concept with Soviet clinical adoption and later operator, hypoxia and maritime research. Healthy-volunteer experiments, clinical reviews and combination proposals answer different questions.